Tonix Pharmaceuticals Holding Corp. (TNXP)
Healthcare
- Fundamental
- 1
- Sentiment
- 1
- Technical
- 4
Do Nothing: fundamentalScore is 1 and qualitativeScore is 1, both below the required floor of 3, so the strategy cannot admit a bullish TNXP entry despite constructive short-term technicals.
Company overview
Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company focused on developing therapeutic agents and diagnostic tools for various human illnesses. Its pipeline includes treatments for immunology, rare conditions, infectious diseases, and central nervous system disorders. Key candidates include TNX-1500 for organ transplant rejection and autoimmune diseases, TNX-2900 for Prader-Willi syndrome, and TNX-102 SL for fibromyalgia and Long COVID.
Fundamental
very weakTonix Pharmaceuticals shows revenue growth but faces significant cash burn and financing risks.
Speculative setup: the company is generating real product revenue growth from TONMYA, but operating losses and cash burn remain very large and recent filings include substantial-doubt going-concern language (cash runway projected only into early Q2 2027). Balance-sheet cash is substantial and debt is limited, but continued funding needs and dilution risk dominate the fundamental profile.
Sentiment
very weakSentiment is overshadowed by funding and cash-burn concerns, despite positive media coverage.
Near-term headlines are dominated by the Aug 10 Q2 2026 earnings update (announced) highlighting TONMYA sales traction; third-party media tone over the last ~14d is modestly positive versus a mildly positive 30–90d baseline. Severe red-flag cap applied due to going-concern/substantial-doubt disclosure (per recent SEC filing referenced upstream), keeping the setup high-risk despite constructive coverage.
Technical
goodThe short-term trend is positive, with price above key moving averages and strong directional momentum.
Score 4/5: short-term trend has turned up above SMA20/SMA50 and EMA9/EMA21, RSI14 is 59.20, MACD is positive above signal and above zero, and ADX14 at 45.74 confirms strong directional momentum; the main technical blemish is that price remains below the SMA200 and under nearby 13.89-14.41 overhead resistance.
You’re looking at 2026-08-18 — more than 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.